Odile Beyne Rauzy - Concepedia

Author

Odile Beyne Rauzy

Also Known As

Beyne Rauzy, Odile, Lin Pierre Zhao, Mikael Ebbo, O Beyne Rauzy, O Rauzy, O. Beyne Rauzy, O. Rauzy, Odile B. Rauzy, Odile Beyne Rauzy, Odile Rauzy

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Université Paris Cité Hôpital Saint-Louis Institut universitaire du cancer de Toulouse Oncopole Assistance Publique – Hôpitaux de Paris Hôpital Lyon Sud

About

Odile Beyne Rauzy is an author at Université Paris Cité specializing in medicine, hematology, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	2	2	115
2	Medicine	2	2	115
3	Emergency Medicine	1	1	59
4	Epidemiology	1	1	59
5	Geriatrics	1	1	59

Odile Beyne Rauzy

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure Thomas Prébet, Steven D. Gore, Benjamin Esterni, Journal of Clinical Oncology	2011	475
Eprenetapopt Plus Azacitidine in <i>TP53</i>-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM) Thomas Cluzeau, Marie Sébert, Ramy Rahmé, Journal of Clinical Oncology	2021	256
Characteristics and outcome of immune thrombocytopenia in elderly: Results from a single center case‐controlled study Marc Michel, Odile Beyne Rauzy, Françoise Roudot Thoraval, American Journal of Hematology ImmunohematologyGeriatric PsychiatryElderly PatientsImmunologyImmunotherapy	2011	59
Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry Benjamin De Valence, M. Delaune, Yann Nguyen, Annals of the Rheumatic Diseases	2023	58
Relation between HLA DRB1 alleles and corticosteroid resistance in giant cell arteritis Odile Beyne Rauzy, M. Fort, Fathi Nourhashemi, Annals of the Rheumatic Diseases	1998	56
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, The Lancet Haematology Hematological MalignancyOncologyHigher-risk Myelodysplastic SyndromesMedicineHematology	2023	56
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience Mathilde Lamarque, Sophie Raynaud, Raphaël Itzykson, Blood	2012	52
Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group Marie Sébert, Thomas Cluzeau, Odile Beyne Rauzy, Blood	2021	43
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with <i>TP53</i> mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML) David A. Sallman, Rami S. Komrokji, Amy E. DeZern, Blood	2021	41
Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome C Farah, C. Bulaï Livideanu, Jérémie Jegu, Journal of the European Academy of Dermatology and Venereology	2010	40

Page 1